drugset / Trial / NCT03680612

Cefepime/AAI101 Phase 2 Study in Hospitalized Adults With cUTI

NCT03680612

Phase 2 Completed 45 enrolled Allecra Medpace, Inc. · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Phase 2, randomised, double-blind, 2-cohort study in hospitalised adults with complicated urinary tract infection (cUTI), including acute pyelonephritis. All study cohorts were randomised in a 2:1 ratio. Treatment duration for each cohort was 7 to 10 days. Patients were not permitted to switch to oral therapy. Cohort 1: 15 patients treated with cefepime 1 g/AAI101 500 mg intravenous (i.v.) infusion over 2 hours once every 8 hours (q8h), and 7 patients treated with cefepime 1 g i.v. infusion over 2 hours q8h. Cohort 2: 15 patients treated with cefepime 2 g/AAI101 750 mg i.v. infusion over 2 hours q8h, and 8 patients treated with cefepime 2 g i.v. infusion over 2 hours q8h.

Timeline

Start
2017-09-05
Primary completion
2018-02-14
Completion
2018-02-14

Drugs

EvaluationDrugModalityDoseRoute
Subject Cefepime Small molecule 1 g Intravenous
Subject Cefepime Small molecule 2 g Intravenous
Subject enmetazobactam Small molecule 500 mg Intravenous
Subject enmetazobactam Small molecule 750 mg Intravenous